Evolv Technologies Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Evolv Technologies Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.91M | Mar 10, 2026 |
| FY2024 | Dec 31, 2024 | $29.10M | Apr 28, 2025 |
| FY2024 | Sep 30, 2024 | $27.36M | Apr 28, 2025 |
| FY2024 | Jun 30, 2024 | $25.22M | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | $22.18M | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | $20.58M | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | $19.96M | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | $18.90M | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | $20.12M | Apr 28, 2025 |
| FY2022 | Dec 31, 2022 | $20.89M | Mar 24, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.30M | Mar 10, 2026 |
| FY2024 | Dec 31, 2024 | $16.74M | Apr 28, 2025 |
| FY2024 | Sep 30, 2024 | $15.81M | Apr 28, 2025 |
| FY2024 | Jun 30, 2024 | $14.58M | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | $12.16M | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | $9.56M | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | $10.89M | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | $6.92M | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | $4.54M | Apr 28, 2025 |
| FY2022 | Dec 31, 2022 | $54.0K | Mar 24, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($33.14M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2024 | ($15.72M) | Apr 28, 2025 |
| FY2024 | Sep 30, 2024 | ($30.44M) | Apr 28, 2025 |
| FY2024 | Jun 30, 2024 | $3.42M | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | ($11.27M) | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | ($17.20M) | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | $5.05M | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | ($67.22M) | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | ($28.68M) | Apr 28, 2025 |
| FY2022 | Dec 31, 2022 | ($28.30M) | Mar 24, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.46M) | Mar 10, 2026 |
| FY2024 | Dec 31, 2024 | ($18.88M) | Apr 28, 2025 |
| FY2024 | Sep 30, 2024 | ($19.15M) | Apr 28, 2025 |
| FY2024 | Jun 30, 2024 | ($22.37M) | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | ($21.91M) | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | ($22.21M) | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | ($21.19M) | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | ($24.09M) | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | ($22.56M) | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | ($102.95M) | Apr 28, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $20.62M | Mar 10, 2026 |
| FY2024 | Dec 31, 2024 | $5.39M | Apr 28, 2025 |
| FY2024 | Sep 30, 2024 | $5.81M | Apr 28, 2025 |
| FY2024 | Jun 30, 2024 | $5.85M | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | $6.40M | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | $6.30M | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | $6.39M | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | $6.39M | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | $5.40M | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | $18.54M | Apr 28, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.67M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($30.85M) | Mar 10, 2026 |
| FY2024 | Jun 30, 2024 | ($37.73M) | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | ($16.15M) | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | ($9.80M) | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | ($8.76M) | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | ($3.43M) | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | ($74.74M) | Apr 28, 2025 |
| FY2024 | Sep 30, 2022 | ($69.43M) | Apr 28, 2025 |
| FY2024 | Jun 30, 2022 | ($52.54M) | Apr 28, 2025 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $3.71M | Mar 28, 2022 |
| FY2021 | Dec 31, 2020 | $6.61M | Mar 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $304.41M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $268.06M | Mar 10, 2026 |
| FY2024 | Jun 30, 2024 | $269.07M | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | $280.00M | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | $297.13M | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | $304.39M | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | $302.43M | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | $304.69M | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | $344.25M | Apr 28, 2025 |
| FY2024 | Sep 30, 2022 | $324.99M | Apr 28, 2025 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $184.99M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $150.41M | Mar 10, 2026 |
| FY2024 | Jun 30, 2024 | $117.85M | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | $140.23M | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | $152.99M | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | $149.66M | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | $159.17M | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | $101.29M | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | $117.63M | Apr 28, 2025 |
| FY2024 | Sep 30, 2022 | $77.17M | Apr 28, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $119.42M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $117.65M | Mar 10, 2026 |
| FY2024 | Jun 30, 2024 | $151.22M | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | $139.78M | Apr 28, 2025 |
| FY2025 | Dec 31, 2023 | $144.14M | Mar 10, 2026 |
| FY2024 | Sep 30, 2023 | $154.73M | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | $143.26M | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | $203.40M | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | $226.62M | Apr 28, 2025 |
| FY2024 | Sep 30, 2022 | $247.82M | Apr 28, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($387.80M) | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | ($354.66M) | Mar 10, 2026 |
| FY2024 | Jun 30, 2024 | ($308.50M) | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | ($311.92M) | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | ($300.65M) | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | ($283.45M) | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | ($288.50M) | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | ($221.28M) | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | ($192.60M) | Apr 28, 2025 |
| FY2024 | Sep 30, 2022 | ($164.47M) | Apr 28, 2025 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $49.15M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $37.02M | Mar 10, 2026 |
| FY2024 | Jun 30, 2024 | $35.70M | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | $44.60M | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | $67.16M | Apr 28, 2025 |
| FY2024 | Sep 30, 2023 | $99.62M | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | $125.89M | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | $181.00M | Apr 28, 2025 |
| FY2024 | Dec 31, 2022 | $229.78M | Apr 28, 2025 |
| FY2024 | Sep 30, 2022 | $218.50M | Apr 28, 2025 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.60M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 10, 2026 |
| FY2023 | Dec 31, 2023 | $0 | Feb 29, 2024 |
| FY2023 | Dec 31, 2022 | $29.68M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $9.95M | Mar 24, 2023 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Jun 30, 2024 | 0 | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Apr 28, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 24, 2023 |
| FY2024 | Sep 30, 2022 | 0 | Apr 28, 2025 |
| FY2024 | Jun 30, 2022 | 0 | Apr 28, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 10, 2026 |
| FY2024 | Jun 30, 2024 | 0 | Apr 28, 2025 |
| FY2024 | Mar 31, 2024 | 0 | Apr 28, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Apr 28, 2025 |
| FY2024 | Jun 30, 2023 | 0 | Apr 28, 2025 |
| FY2024 | Mar 31, 2023 | 0 | Apr 28, 2025 |
| FY2022 | Dec 31, 2022 | 0 | Mar 24, 2023 |
| FY2024 | Sep 30, 2022 | 0 | Apr 28, 2025 |
| FY2024 | Jun 30, 2022 | 0 | Apr 28, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 175.40M | Mar 10, 2026 |
| FY2025 | Dec 31, 2024 | 159.60M | Mar 10, 2026 |
| FY2024 | Dec 31, 2023 | 151.31M | Apr 28, 2025 |
| FY2023 | Dec 31, 2022 | 145.20M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 142.75M | Mar 24, 2023 |
| FY2021 | Dec 31, 2020 | 9.85M | Mar 28, 2022 |